Publicacions en col·laboració amb investigadors/es de Hospital Infanta Leonor (59)

2024

  1. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

    International Journal of Dermatology, Vol. 63, Núm. 4, pp. 503-511

  2. Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain

    Dermatologic Therapy, Vol. 2024

  3. Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 10-20

  4. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice

    Journal of the European Academy of Dermatology and Venereology, Vol. 38, Núm. 9, pp. 1783-1790

  5. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study

    Actas Dermo-Sifiliograficas

  6. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry

    British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363

  7. Validation of the Spanish Version of the PURE-4 Questionnaire for the Early Detection of Psoriatic Arthritis in Psoriatic Patients

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 7, pp. 654-662

2023

  1. Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study

    JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 488-501

  2. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

    Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326

  3. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  4. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)

    Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345

  5. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment

    Dermatology and Therapy, Vol. 13, Núm. 3, pp. 673-688

  6. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

    International Journal of Dermatology

  7. Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 10, pp. 865-883

  8. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 9, pp. 755-762

2022

  1. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Dermatologic Therapy, Vol. 35, Núm. 2

  2. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting

    Dermatologic Therapy, Vol. 35, Núm. 8

  3. Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406

  4. Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness

    Expert Opinion on Biological Therapy

  5. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

    Dermatologic Therapy, Vol. 35, Núm. 12